Zobrazeno 1 - 4
of 4
pro vyhledávání: '"Donna Wegner"'
Autor:
Donna Wegner, Matthews George, Reginald Lee, Minyanga Nkhoma, J. Thomas Brenna, Iona Humpheries-Cuff, Hui Gyu Park, R.J. Scott Lacombe, Meghan Callaghan-Gillespie, Kenneth Maleta, Richard L Canfield, Mark J. Manary, Kevin Stephenson
Publikováno v:
The American Journal of Clinical Nutrition. 115:1322-1333
BACKGROUND There is concern that the polyunsaturated fatty acid (PUFA) composition of ready-to-use therapeutic food (RUTF) for treatment of severe acute malnutrition (SAM) is suboptimal for neurocognitive recovery. OBJECTIVE We tested the hypothesis
Autor:
David Taylor Hendrixson, Aminata Shamit Koroma, Alyssa Los, Mark J. Manary, Destiny Krietemeyer, Robert H. J. Bandsma, Claire Godbout, Donna Wegner, Natasha Lelijveld
Publikováno v:
The American Journal of Clinical Nutrition. 114:955-964
BACKGROUND: There is a lack of consensus on what is the most appropriate treatment of moderate acute malnutrition (MAM). OBJECTIVES: We aimed to determine if provision of ready-to-use-therapeutic food (RUTF) and antibiotics to "high-risk" MAM (HR-MAM
Autor:
Breanne Langlois, Devika Suri, Donna Wegner, Stacy Griswold, Amir Hassan, Ilana R Cliffer, Mark J. Manary, Stephen A. Vosti, Beatrice Rogers, Irwin H. Rosenberg, Aminata Shamit Koroma, Patrick Webb, Shelley Walton, Ken Chui, Ye Shen
Publikováno v:
The American Journal of Clinical Nutrition
Background Moderate acute malnutrition (MAM) affects 33 million children annually. Investments in formulations of corn-soy blended flours and lipid-based nutrient supplements have effectively improved MAM recovery rates. Information costs and cost-ef
Autor:
Melody Mui, David Taylor Hendrixson, Taylor Bryant, Claire Godbout, Donna Wegner, Aminata Shamit Koroma, Mark J. Manary, Meghan Callaghan-Gillespie, Alyssa Los
Publikováno v:
Gut. 69:2143-2149
ObjectiveWe hypothesised that an alternative RUTF (ready-to-use therapeutic food) made with oats (oat-RUTF) would be non-inferior to standard RUTF (s-RUTF).DesignThis was a randomised, triple-blind, controlled, clinical non-inferiority trial comparin